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862Objective: Acute clinical deterioration preceding death is a common observation in patients with advanced
interstitial lung disease and secondary pulmonary hypertension. Patients with pulmonary arterial hypertension
refractory to medical therapy are also at risk of sudden cardiac death (cor pulmonale). The treatment of these
patients remains complex, and the findings from retrospective studies have suggested that intubation and me-
chanical ventilation are inappropriate given the universally poor outcomes. Extracorporeal support technologies
have received limited attention because of the presumed inability to either recover cardiopulmonary function in
the patient with end-stage disease or the presumed inability to proceed to definitive therapy with transplantation.
Methods: A retrospective review was performed of 31 patients from 2 institutions placed on extracorporeal
membrane oxygenation as a bridge to lung transplantation compared with similar patients without extracorpo-
real membrane oxygenation at the same institutions and comparison groups queried from the United Network for
Organ Sharing database.
Results:Wehave transplanted 31 patientswith refractory lung disease frommechanical artificial lung support. Of the
31 patients, 19 were ambulatory at transplantation. Pulmonary fibrosis (42%), cystic fibrosis (20%), and pulmonary
hypertension (16%) were the most common diagnostic codes and acute cor pulmonale (48%) and hypoxia (39%)
were the most common indications for device deployment. The average duration of extracorporeal membrane oxy-
genation support was 13.7 days (range, 2-53 days), and the mean survival of all patients bridged to pulmonary trans-
plantation was 26 months (range, 54 days to 95 months). The 1-, 3-, and 5-year survival was 93%, 80%, and 66%,
respectively. The duration of in-house postoperative transplant care ranged from 12 to 86 days (mean, 31 days).
Patients requiring an extracorporeal membrane oxygenation bridge had comparable survival to that of the high acuity
patients transplanted without extracorporeal membrane oxygenation support in the Scientific Registry of Transplant
Recipients database but were at a survival disadvantage compared with the high-acuity patients (lung allocation
score,>50) transplanted at the same center who did not require mechanical support (P<.001).
Conclusions: These observations challenge current assumptions about the treatment of selected patients with
end-stage lung disease and suggest that ‘‘salvage transplant’’ is both technically feasible and logistically viable.
Widespread adoption of artificial lung technology in lung transplant will require the design of clinical trials that
establish the most effective circumstances in which to use these technologies. A discussion of a clinical trial and
reconsideration of current allocation policy is warranted. (J Thorac Cardiovasc Surg 2013;145:862-8)Implementation of the lung allocation scoring (LAS) sys-
tem has decreased the overall waitlist mortality for patients
needing pulmonary transplantation.1 However, specific
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The Journal of Thoracic and Cardiovascular Surgpulmonary hypertension and medically refractory pulmo-
nary arterial hypertension—remain at high risk of acute
clinical decompensation and have not been afforded the
same waitlist survival advantage.2 Mechanical ventilation
is not an effective management strategy for patients with
end-stage lung disease awaiting transplantation3 and ‘‘insti-
tuting assisted ventilation in patients with predominantly
fibrotic forms of interstitial lung disease is of questionable
value, perhaps even futile.’’4 We describe our experience
with extracorporeal technologies (extracorporeal mem-
brane oxygenation [ECMO]) as a bridge to transplantation
in patients with fulminant respiratory failure and present
an institutional algorithm for the treatment of ‘‘transplant
eligible’’ patients with acute respiratory syndromes.
METHODS
We performed a retrospective review of prospectively collected data of
all patients undergoing ECMO as a bridge to lung transplantation fromery c March 2013
Abbreviations and Acronyms
BOS ¼ bronchiolitis obliterans syndrome
ECMO ¼ extracorporeal membrane oxygenation
LAS ¼ lung allocation score
PEA ¼ pulseless electrical activity
PECLA ¼ pumpless extracorporeal lung assist
RV ¼ right ventricular
UNOS ¼ United Network for Organ Sharing
VA ¼ venoarterial
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nia, San Francisco, School of Medicine and University of Kentucky
College of Medicine). All patients followed an ECMO deployment algo-
rithm managed by a single surgeon (Figure 1).
We compared the survival of these patients (ECMO group) with that
of other lung transplant patients from our institutions with LAS scores
greater than 50 (LAS score >50 group) and 2 other patient groups
queried from the United Network for Organ Sharing (UNOS) database.
The UNOS groups included isolated double lung transplants performed
from May 2005 to June 2011 with a transplantation diagnosis of cystic
fibrosis, idiopathic pulmonary fibrosis, or pulmonary arterial hypertension
and a LAS score greater than 50: without ECMO (UNOS LAS score>50
group) and with ECMO (UNOSECMOgroup) at the time ofmatching. The
3-year survival was compared across the 4 groups using the Kaplan-Meier
method and the log-rank test. Statistical analyses were performed using
SPSS, version 19.0, software (SPSS, Chicago, Ill).
ECMO Deployment
An algorithm for ECMOdeployment is shown in Figure 1. Using this al-
gorithm, all mechanically ventilated patients with hemodynamic instability
and/or acute respiratory failure undergo open femoral cannulation for stabi-
lization using venoarterial ECMO (femoral arterial cannula and a long ve-
nous cannula deployed to the right atrium). Patients are weaned from
paralytics, sedation, and vasopressor support. We deployed an 8F distal
femoral arterial flow cannula if clinically indicated to preclude limb ische-
mia; however, this is rarely necessary during the initial deployment (30%
incidence).We do not consider femoral venoarterial (VA) ECMO an appro-
priate method of long-term support, because it precludes ambulatory status.
In awake patients with nonfocal neurologic examination findings and ade-
quate end organ perfusion, the VA ECMO blood path is reversed and the
centrifugal pump excluded from the circuit—arteriovenous pumpless
extracorporeal lung assist (PECLA). Native cardiac output generates flows
of 1.6 to 2.2 L/min from the femoral arterial cannula through the Quadrox
oxygenator, with return to the right atrium. Patients who remain hemody-
namically stable—even with low oxygen saturation—can be converted to
venovenous ECMOwith a dual lumen catheter after 30 minutes of femoral
PECLA support. Echocardiographic evaluation during PECLA support has
proved a useful adjunct in assessing global ventricular function and evi-
dence of cor pulmonale (right ventricular [RV] to left ventricular ratio in di-
astole, quantification of tricuspid valvular insufficiency, and inadequate left
ventricular preload). Patients with ongoing hemodynamic requirements
(RV failure/pulmonary hypertension) are converted to central cannulation
(right atrium [RA] to pulmonary artery [PA], PA to left atrium, RA to
ascending aorta)with off-label use of availableventricular assist device can-
nulas (Thoratec PVAD, Pleasanton, Calif; Abiomed AB5000, Danvers,
Mass). Cannulation is by median sternotomy or bilateral anterolateral tho-
racotomy, depending on the subsequent planned operation (eg, heart–lung,
bilateral lung) and the acuity of deployment.
‘‘Hybrid ECMO’’ with venovenous duel lumen cannula support and an
associated atrial septostomy5 has proved useful in patients who requireThe Journal of Thoracic and Camechanical support and are not considered candidates for central cannula-
tion. In our experience, induction anesthesia and mechanical ventilation
precipitate cardiovascular collapse (pulseless electrical activity [PEA]) in
nearly one half of the patients presenting with end-stage RV failure related
to pulmonary arterial hypertension. These patients are placed directly on
VA ECMO under local anesthesia. Venoarteriovenous ECMO with a dual
lumen venovenous cannula and simultaneous postoxygenator blood return
to both the right atrium and right subclavian artery has also proved an
effective mode of support in ambulatory patients.6
All patients receive continuous intravenous heparin with a target acti-
vated clotting time of 140 to 180 seconds. We use a QUADROX
oxygenator and centrifugal pump (Thoratec CentriMag) for long-term ex-
tracorporeal support (>72 hours). No protocols have defined the absolute
criteria for transfusion or laboratory analysis, and one half the patients re-
ceived transfusions before transplantation. All patients mechanically ven-
tilated at ECMO support underwent tracheostomy. All donor lungs fulfilled
standard criteria. All transplants were performed with cardiopulmonary
bypass. Any neurologic deficit was a contraindication to continued
ECMO bridge support.
Ambulatory ECMO Approach
Starting in 2005, all ECMO-supported patients were subject to an
ambulatory management program. All patients were weaned off sedation
and were awake after ECMO deployment. The patients were evaluated
by a multidisciplinary team involving physical and occupational therapy,
respiratory therapy, speech pathology, and a nutritionist. Once hemody-
namic stability was achieved (weaned off vasopressors), the patients
were assisted by the multidisciplinary team and began ambulation trials
with a goal to ambulate more than 200 ft before transplantation. A perfu-
sion specialist was availablewhile the patients ambulated to assist the nurs-
ing personnel with the ECMO circuit. Physical therapy also provided range
of motion and weight lifting limb exercises to improve upper and lower
extremity strength. The patients were allowed to eat by mouth if the
swallow evaluation findings were normal.RESULTS
From January 2003 to June 2012, 31 patients were
bridged to lung transplantation from an ‘‘ECMO bridge.’’
Patient age and gender, transplant date, diagnosis, indica-
tion for ECMO, duration of support (days), cannulation
strategy, operation, and outcomes are listed in Table 1. Of
the 31 patients, 18 were ambulatory at transplantation.
The etiology of the postoperative deaths included noncom-
pliance in retransplanted cystic fibrosis (patient 1, recurrent
multidrug-resistant pseudomonas pneumonia), bronchio-
litis obliterans syndrome (BOS) beyond 5 years with renal
dysfunction precluding repeat transplantation (patient 2),
BOS at 34 months with performance status precluding re-
peat transplantation (patient 4), multiorgan system failure
at 10 months in an outside hospital patient (patient 12),
metastatic adenocarcinoma with an unknown primary at
13 months (patient 13), and technical misadventure (cata-
strophic air embolus/patent foramen ovale, patient 21).
Three patients (patients 9, 23, and 24) were not receiving
mechanical ventilation at ECMO cannulation. Patient 5
(with acute respiratory distress syndrome) underwent repeat
transplantation from venovenous duel lumen cannula
ECMO (University of Iowa) in February 2012 (BOS/hyp-
oxia). One patient continued with ECMO after implantationrdiovascular Surgery c Volume 145, Number 3 863
FIGURE 1. Management algorithm for potential bridge to transplant candidates. All hemodynamically unstable patients with respiratory or cardiopulmo-
nary failure and patients requiring transport were stabilized with femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO). Within 72 hours
of deployment, patients who are awake (‘‘neuro intact’’) and without inotropic requirement have the ECMOblood path reversed (femoral arteriovenous [AV]
ECMO) without centrifugal pump support (pumpless extracorporeal lung assist [PECLA]). Patients tolerating PECLAwere converted to venovenous (VV)
dual lumen cannula (DLC) support in preparation for ambulation. Patients with ongoing need for inotropic or centrifugal pump support were converted to
central cannulation or hybrid venoarteriovenous (VAV) ECMO in preparation for ambulation. pAO2,Arterial partial pressure of oxygen; pCO2, partial pres-
sure of carbon dioxide;MV,mechanical ventilation; hrs, hours; trach, tracheostomy; neuro, neurologic; nl, normal;ECHO, echocardiogram; abnl, abnormal;
BAS, balloon atrial septostomy; RA, right atrium; PA, pulmonary artery; LA, left atrium; Ao, ascending aorta.
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RA to ascending aorta for 3 days). Excluding the perioper-
ative death (patient 21), all patients were discharged from
the hospital. The duration of in-house postoperative trans-
plant care ranged from 12 to 86 days (mean, 31 days).
Three patients had significant complications of device de-
ployment. Patient 8 required reoperation 3 days after ECMO
for cardiac tamponade and repositioning of the pulmonary
artery outflow graft. Patient 21 underwent a cannula ex-
change for a fracture of the dual lumen Avalon venovenous
ECMOcircuit on post-ECMOday 10—this was unrelated to
the subsequent perioperative death. Patient 18, a 21-year-old
woman with pulmonary veno-occlusive disease who under-
went 28 days of femoral VA ECMO for cardiopulmonary
collapse, was unable to ambulate after an unremarkable bi-
lateral lung transplant. Subsequent magnetic resonance im-
aging findings were consistent with ‘‘watershed’’ ischemia
of the proximal thoracic spinal cord. We considered this
a complication of prolonged retrograde perfusion common
to the femoral VA ECMO blood path but are unaware of
any previous reports of a similar complication. The patient
regained normal ambulatory status but the requirements of
neurologic rehabilitation accounted for the longest period
of post-transplant care within the case series (86 days).
The 1- and 3-year actuarial survival for the ECMO group
was 93% and 83%, respectively (Figure 2). This was
significantly worse than the survival for similar patients
transplanted without mechanical support (LAS score>50864 The Journal of Thoracic and Cardiovascular Surggroup, P < .001). Approximately 30% of the patients
transplanted without ECMO had been hospitalized before
transplantation, and the outcomes of the LAS score>50
group were statistically better than predicted (P < .05;
www.SRTR.org). Survival of the ‘‘ECMO bridge’’ patients
was statistically significantly better than that of the 2 UNOS
comparison groups (UNOS LAS score >50 and UNOS
ECMO; P<.001).
DISCUSSION
The present case series had the limitations common to all
retrospective data analyses, and it is difficult to make legit-
imate comparisons among the recent reports of ECMO as
a bridge to transplantation. Regional differences in organ
allocation policy, institutional differences in the logistic
design and deployment criteria of extracorporeal circuits,
and surgeon-specific preferences regarding organ selection
and operative technique can have a profound effect on the
outcomes. Nonetheless, in the present case series, the sur-
vival of patients ‘‘ECMO bridged’’ to transplant was 97%
at 30 days. The 1-year outcomes of the patients transplanted
from an ECMO bridge exceeded 90%, the 3-year outcomes
exceeded 80%, and 3 patients have survived beyond 5 years
(66%)—1 of whom underwent repeat transplantation from
a second ECMO bridge for BOS 68 months after his origi-
nal implant date. However, although the survival data
within the present case series were comparable or superior
to those previously reported,7,8 high acuity patients (LASery c March 2013
TABLE 1. Patient demographics
Pt. no. Age (y), gender, surgery date Diagnosis Indication DOS (d) Cannulation Procedure Outcome
1 33, M, 10/03 CF/BOS Hypoxia 2 VA (f) Repeat BLTx Death at 14 mo (NC)
2 44, M, 4/04 IPF RV/PEA 5 VA (f) BLTx Death at 61 mo (BOS)
3 52, M, 7/04 IPF RV/PEA 7 VA (f) BLTx
4 61, M, 7/05 IPF RV/PEA 3 (3) VA (f), (RA to Ao) BLTx Death at 34 mo (BOS)
5 28, M, 6/06 ARDS Hypoxia 3 VV BLTx
6 32, F, 1/08 CF Hypoxia 3 VA (f) BLTx
7 61, F, 3/08 Scl/ILD RV/PEA 6 VA (f) BLTx
8* 58, M, 1/09 IPF Hypoxia/PEA 11 RA to Ao BLTx
9* 59, M, 2/09 BOS Hypoxia 11 VV (DL) BLTx
10* 32, F, 2/09 PPHTN PEA 13 RA to Ao HLTx
11 15, F, 7/09 PVOD RV/PEA 16 VA (f) BLTx
12* 48, M, 2/10 Dm/ILD RV/PEA 33 VA (f), PA to LA BLTx Death at 10 mo (MOSF)
13* 64, M, 3/10 PHTN RV/PEA 20 PA to LA BLTx Death at 13 mo (ACA)
14* 39, M, 5/10 CF/BOS Hypoxia 4 VV (DL) Repeat BLTx
15* 49, M, 5/10 Sarcoid RV/PEA 14 RA to Ao HLTx
16* 48, M, 6/10 AIP Hypoxia 24 VV, RA to PA BLTx
17* 32, M, 6/10 IPF IPF 36 PA to LA BLTx
18 21, F, 7/10 PVOD RV/PHTN 28 VA (f) BLTx
19* 25, F, 8/10 CF/BPF Hypercarbia 14 VV (DL) BLTx
20* 35, M, 1/11 CF Hypoxia 2 VV (DL) BLTx
21 51, M, 3/11 IPF Hypoxia 18 VV (DL), VA(f) BLTx Death POD1 (neuro)
22 40, F, 4/11 Scl/ILD Hypoxia 2 VA (f) BLTx
23* 68, M, 4/11 CWP PHTN (ei) 3 VV (DL) BLTx
24* 68, F, 4/11 PVOD Syncope 2 VV (DL)/septostomy BLTx
25* 23, F, 5/11 CF Hypoxia 15 VV (DL) BLTx
26 59, M, 6/11 IPF RV/PEA 4 VA (f) BLTx
27* 26, M, 8/11 ARDS Hypoxia 53 VV (DL) BLTx
28* 52, F, 12/11 CF Hypoxia 13 VAV hybrid BLTx
29* 65, M, 1/12 IPF Hypoxia/RV 6 VV (DL) BLTx
30 47, M, 1/12 IPF Hypoxia/RV 4 VA (f) BLTx
31* 53, M, 4/12 ARDS Hypoxia 48 VV (DL) BLTx
Pt. no., Patient number; DOS, duration of support;M, male; CF, cystic fibrosis; BOS, bronchiolitis obliterans syndrome; VA (f), venoarterial (femoral vein to femoral artery/ret-
rograde); BLTx, bilateral lung transplantation; NC, nasal cannula; IPF, idiopathic pulmonary fibrosis; RV, right ventricular; PEA, pulseless electrical activity; RA to Ao, right
atrium to ascending aorta (‘‘walking bypass’’); RA to PA, right atrium to pulmonary artery (‘‘oxyRVAD’’); ARDS, acute respiratory distress syndrome; VV, venovenous extra-
corporeal membrane oxygenation (internal jugular to femoral vein, femoral vein to internal jugular); F, female; Scl, scleroderma; ILD, interstitial lung disease; VV (DL), veno-
venous right internal jugular dual lumen cannula; PPHTN, persistent pulmonary hypertension;HLTx, heart–lung transplantation; PVOD, pulmonary veno-occlusive disease;Dm,
dermatomyositis; PA to LA, pulmonary artery to left atrium (‘‘pulmonary bypass’’); MOSF, multiorgan system failure; PHTN (ei), pulmonary hypertension; ACA, adenocarci-
noma; AIP, acute interstitial pneumonitis; BPF, bronchopleural fistula; POD, postoperative day; neuro, neurologic; VAV (hybrid), right internal jugular dual lumen catheter with
both right subclavian artery and right internal jugular return; CWP, coal workers’ pneumoconiosis. *Patients ambulatory at transplantation (n ¼ 18).
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bridge were at a survival disadvantage compared with
high acuity patients (LAS score>50) who did not require
mechanical support. In contrast, patients in our case series
transplanted from an ECMO bridge were at a survival
advantage compared with patients with an LAS score
greater than 60 in the national Scientific Registry of
Transplant Recipients database (76.7% 1-year survival;
www.SRTR.org). Although the costs were approximately
30% greater for patients transplanted from an ECMO
bridge than for patients transplanted from home, the cost
differential was less compared with in-house patients with
LAS scores exceeding 50 who did not require mechanical
support. Although several ‘‘bridged’’ patients have returned
to either partial or fulltime employment, we do not have
adequate data to calculate the ‘‘cost per life-year saved.’’The Journal of Thoracic and CaGiven the logistic and fiduciary burden, it is worth con-
sidering the efficacy of ECMO bridging in pulmonary trans-
plantation. Four patients UNOS listed for transplantation
and placed on ECMO for clinical decompensation had with-
drawal of care. These included VA femoral cannulation of
a 60-year-old man with scleroderma/pulmonary hyperten-
sion (after PEA arrest) and evidence of worsening systemic
vasculitis, a 47-year-old woman with sarcoidosis who un-
derwent delayed femoral cannulation for cor pulmonale/
PEA arrest and progressed to anoxic brain death (post-
ECMO day 3), a 68-year-old man with idiopathic
pulmonary fibrosis and secondary pulmonary hypertension
who developed progressive RV failure after deployment of a
venovenous dual lumen cannula (Avalon), and a 61-year-
old man with interstitial lung disease receiving immunosup-
pressive therapy who was converted from venovenous duelrdiovascular Surgery c Volume 145, Number 3 865
FIGURE 3. Institutional epidemiology of 100 sequential extracorporeal
life support deployments (86 patients), single-surgeon experience (2005 to
June 2012). Approximately 30% of extracorporeal membrane oxygenation
(ECMO) deployments were for respiratory failure in non-United Network
for Organ Sharing waitlisted patients potentially qualifying for pulmonary
transplant by disease diagnosis, age, and known associated comorbidities
(n ¼ 26). Of these, 8 recovered (‘‘bridge to recovery’’). Of the remaining
18 ‘‘salvage ECMO’’ patients, 7 were listed for transplantation and received
allografts. The remaining 11 patients had withdrawal of support in the ab-
sence of viable transplant candidacy. tx, Transplantation; OSH, outside
hospital; RV, right ventricular; ILD, interstitial lung disease; PHTN, pulmo-
nary hypertension; LV, left ventricular; HTN, hypertension; H1N1, H1N1
influenza; PGD, primary graft dysfunction.
FIGURE 2. Kaplan-Meier 3-year survival for patients transplanted from
an extracorporeal membrane oxygenation (ECMO) bridge (Series
ECMO, n ¼ 31, green) and patients on our institutional waitlist with
lung allocation system (LAS) scores greater than 50 transplanted during
the same period (June 2005 through June 2012) without mechanical sup-
port (Series LAS score>50, n ¼ 69, blue). The institutional outcomes
were compared with similar patients from the United Network for Organ
Sharing (UNOS) data set transplanted without ECMO support (UNOS
LAS score>50 group, n ¼ 2971, red) and UNOS registry patients sup-
ported with ECMO at transplantation (UNOS ECMO group, n ¼ 47, pur-
ple). Survival varied significantly among the groups (log-rank P<.001).
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aorta) and subsequently developed multiorgan system fail-
ure/fungal sepsis. Overall, the conversion rate from
ECMO bridge to transplant for patients currently listed in
UNOS at ECMO support is 87% (31/35).
We consider patients with acute respiratory failure syn-
dromes—who are not UNOS listed at initial ECMO sup-
port—to be candidates for transplant from an ECMO
bridge. This population of ‘‘salvage transplants’’ represents
27% of the present case series (patients 5, 8, 15, 16, 17, 27,
and 31). These patients were all transferred with mechani-
cal ventilation from an outside hospital with fulminant
respiratory failure (1 ECMO transport, 2 on ECMO before
transfer). Decisions regarding whether patients accepted
from an outside institution for ECMO are receiving
ECMO as a ‘‘bridge to recovery’’ or ‘‘bridge to transplant’’
is contingent on the clinical course and underlying diagno-
sis. On the basis of the institutional epidemiology of
ECMO/extracorporeal life support from 2005 to 2012
(Figure 3), one half of the potential candidates (7 of 18)
in whom pulmonary function failed to recover and were
otherwise candidates for transplantation have received allo-
grafts (40% conversion rate). This observation should in-
form subsequent discussions as to whether the ‘‘ECMO
bridge’’ is an evolving standard of care9 or a specialty prac-
tice limited to regional referral centers.10 An ‘‘awake’’
patient who does not meet the viability criteria for subse-
quent transplantation presents a significant logistic and
ethical critical care dilemma.866 The Journal of Thoracic and Cardiovascular SurgThe emphasis of contemporary reports on patient ‘‘bridg-
ing and improvement’’11 and the ‘‘support for ambulatory
patients without mechanical ventilation’’12,13 is consistent
with our experience during the past decade. Since January
2006, all patients have been awake and interactive, and 19
patients were ambulatory at transplantation. We routinely
preclude active listing of ECMO-supported patients with
UNOS until they reach a ‘‘threshold of viability.’’ To that
end, the ‘‘ECMO bridge to transplant’’ can provide an effec-
tive method of pulmonary allograft resource allocation to
the sickest of patients, who are likely to benefit. If ECMO
is to become for pulmonary transplantation what ventricular
assist devices have become for cardiac transplantation, the
parameters of effective device deployment will need to be
integrated into the current lung allocation system.
Although all extracorporeal technologies share the gener-
alized risk profile of bleeding and thrombosis, our clinical
failures were not device related. Inappropriate patient selec-
tion and delayed deployment of appropriate technology
have been significant predictors of poor patient outcomes.
We do not consider the use of an ‘‘ECMO bridge’’ to pulmo-
nary transplantation an isolated surgical procedure. Theery c March 2013
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tracorporeal technology that will effectively bridge a patient
with cystic fibrosis with hypercapnic respiratory failure is
markedly different than the device technology required to
support a patient with idiopathic pulmonary fibrosis with
cor pulmonale and PEA arrest. The clinical goal is an am-
bulatory patient without respiratory failure and a risk profile
for transplantation significantly less than that at the initia-
tion of initial ECMO support. This clinical thought process
mirrors that of current ventricular assist device management
paradigms in cardiac transplantation.
The broad application of artificial lung technologies to
support patients with advanced lung disease has significant
public health and policy implications. Most UNOS wai-
tlisted patients described in the present report underwent
emergent cannulation in the context of progressive disease
(eg, accelerated decompensation phase of pulmonary fibro-
sis with secondary pulmonary hypertension and cardiopul-
monary collapse). An additional group of patients had
parenchymal disease not amenable to traditional support
with mechanical ventilation (eg, uncontrolled bronchopleu-
ral fistula in cystic fibrosis). Transplantation before decom-
pensation would have precluded the need for mechanical
support. As noted in the outcomes analysis, our institutional
UNOS waitlisted patients with LAS scores greater than 50
who avoided ECMO support had a significant survival ad-
vantage. An analysis of lung transplants performed from
May 2006 to December 2006within UNOS region 5 demon-
strated that only 4% of transplanted patients had LAS scores
greater than 70 (unpublished data). LAS scoreswithin the lo-
cal donor-specific area were predictive, with the waiting
time reduced by one half for every 5 points greater than an
LAS score of 30. The estimated wait time for a patient
with an LAS score greater than 50 was less than 14 days.
Had organ allocation been regionalized rather than local, it
is possible that several patients ‘‘rescued’’ with an ECMO
bridge might have undergone transplantation before clinical
decompensation. A discussion of more ‘‘regionalized’’
(nonlocal) allocation of pulmonary allografts—similar to
that currently in place for cardiac allografts—is warranted.
CONCLUSIONS
The use of extracorporeal technologies to salvage,
rehabilitate, and, subsequently, transplant patients with
nonrecoverable lung disease is technically doable and
logistically feasible. Progression of chronic disease with
unpredictable and fulminant decompensation (pulmonary
fibrosis and pulmonary hypertension), mechanical compli-
cations of an established lung disease (bronchopleural fis-
tula in cystic fibrosis), and respiratory failure syndromes
without efficacious medical therapy (pulmonary veno-
occlusive disease) are the diagnostic categories most likely
to demonstrate a survival benefit from the application
of extracorporeal mechanical support. Algorithm-directedThe Journal of Thoracic and Camanagement of ECMO deployment can improve survival.
An informed registry of the relevant parameters predicting
successful usage of current technologies is necessary and
discussion of an appropriately constructed clinical trial is
warranted.
Some of the data used in the present report were from the UNOS
database and the participating centers. UNOS did not review the
analysis and is not responsible for our conclusions.
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Dr Michael S. Mulligan (Seattle, Wash). Thanks, Chuck. That
represents a lot of work. Very nice paper, and certainly you have
done a lot to push the envelope and advance the field. I have
a few questions for you.
The first is that I notice there were 5 nonretransplant patients
with cystic fibrosis (CF). When they present hypoxic and in hyper-
carbic failure, they are intubated and then begin to retain infected
secretions. Their time on the ventilator is very poorly tolerated and
often quickly progress to sepsis. Conversely, the ‘‘crashing idio-
pathic pulmonary fibrosis (IPF)’’ patient historically does poorly
in long-term outcomes. I was wondering how the patients withrdiovascular Surgery c Volume 145, Number 3 867
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XCF fared and is this something we can do to provide advantages for
them going forward?
Dr Hoopes. From our perspective, patients with CF are ideal
patients because they are less unstable hemodynamically when
they present. For patients with CF, we have deployed ECMO in
response to mechanical complications of the disease, primarily
complications of uncontrolled bronchopleural fistula when
patients could not be adequately ventilated. We have very few
absolute exclusions to transplant, but we will not transplant
someone who is not ambulatory. In the past 4 years, CF patients
with profound hypoxia or hypercarbia secondary to disease
burden who have required mechanical ventilation have under-
gone tracheostomy and transition to venovenous ECMO with
the expectation that they all become ambulatory prior to
transplantation.
Dr Mulligan. So perhaps you are intervening a bit earlier than
some of the other centers. Intervening later seems to be associated
with survival outcomes that are not quite as good.
The second question I have for you relates to the LAS scoring.
Currently, if you consider all theUNOSdata, the use ofpretransplant
ECMO carries a post-transplant odds ratio for mortality of 7. Your
own institutional data showed a negative effect on outcomes, and,
currently in theUNOSbylaws, noLAS adjustment ismade for being
on ECMO. Given that so many of your patients were listed patients,
how did you adjust the LAS score when they went on ECMO?
Dr Hoopes. LAS scores reflect the amount of oxygen and the
need for mechanical ventilation as the vast majority of patients
were intubated and transitioned from mechanical ventilation to
ECMO support. From a philosophical standpoint, I would argue
that we are going to ultimately end up the same place we are
when we consider our cardiac patients with ventricular assist868 The Journal of Thoracic and Cardiovascular Surgdevices. We will actually start lowering the scores of patients on
ECMO and deprioritizing them, not increasing their priority score
because they would be more stable and actually reperesent a lower
risk profile recipient. As you note, currently ECMO cannot be
effectively integrated into the LAS system. Nonetheless, in the
majority of patients, life-sustaining extracorporeal life support is
inherently unstable and we have listed them as though they were
receiving mechanical ventilation.
Dr Mulligan. The last question relates to your call for regional
sharing. The benefits to critically ill recipients have been outlined;
however, significant issues exist with implementing such strate-
gies. Specifically, one would have to very carefully standardize
the listing behavior and practices to avoid ‘‘gaming’’ of the sys-
tem. One would also have to try to make organ acceptance behav-
iors fairly uniform. Can you speak to some of these barriers to
regional sharing?
Thank you very much. Excellent paper.
Dr Hoopes. We are in total agreement. My frustration with
transplantation is that it is not currently studied as a public health
issue. It is currently viewed as ‘‘my list versus your list,’’ and I do
not think, under the current system, it would be possible to actually
make an LAS system that takes into account regionalization versus
local program interests. What I would advocate for in the long run
is regionalization of transplantation as a public health resource.
Perhaps not all transplant centers need to provide artificial lung
technologies. How national health care policy would establish re-
gional referral centers, what such centers would actually do, and
how they would be structured and reimbursed would obviously
be contentious. As you know, regionalization has been discussed
in the past and the political wherewithal to truly study the issue
has been missing.ery c March 2013
